Sorrisos: O=C([O-])CCSC[C@@H]1[C@@H](O[C@@H]2O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]3O[C@H](CSCCC([O-])=O)[C@@H](O[C@H]4[C@H](O)[C@@H](O)[C@H](O5)[C@@H](CSCCC([O-])=O)O4)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O[C@H]7[C@H](O)[C@@H](O)[C@@H](O[C@H]8[C@H](O)[C@@H](O)[C@H]5O[C@@H]8CSCCC([O-])=O)O[C@@H]7CSCCC([O-])=O)O[C@@H]6CSCCC([O-])=O)O1.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]
Inchi: InChI=1S/C73H112O48S8/c74-34(75)1-9-122-17-26-56-42(90)49(97)67(107-26)116-58-28(19-124-11-3-36(78)79)109-69(51(99)44(58)92)118-60-30(21-126-13-5-38(82)83)111-71(53(101)46(60)94)120-62-32(23-128-15-7-40(86)87)113-73-65(54(62)102)105-25-104-64-55(103)72(112-33(63(64)121-73)24-129-16-8-41(88)89)119-61-31(22-127-14-6-39(84)85)110-70(52(100)47(61)95)117-59-29(20-125-12-4-37(80)81)108-68(50(98)45(59)93)115-57-27(18-123-10-2-35(76)77)106-66(114-56)48(96)43(57)91/h26-33,42-73,90-103H,1-25H2,(H,74,75)(H,76,77)(H,78,79)(H,80,81)(H,82,83)(H,84,85)(H,86,87)(H,88,89)/t26-,27-,28-,29-,30-,31-,32-,33-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54+,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-/m1/s1
Analytical method development and validation for the estimation of sugammadex
By Parekh, Hemangi; Chokshi, Parin; Mashru, Rajashree
From Journal of Drug Delivery and Therapeutics (2020), 10(1), 52-59.
Determination of sugammadex in human plasma, urine, and dialysate using a high-performance liquid chromatography/tandem mass spectrometry assay
By de Zwart Marcel A H; ten Bruggencate-Broeders Jolanda; van Hal Henk J M; Megens Rene H J J J; Frasa Helma W L H
From Journal of chromatography. B, Analytical technologies in the biomedical and life sciences (2011), 879(19), 1573-86.